Fri, February 1, 2013
Thu, January 31, 2013

Martin Auster Maintained (BMRN) at Strong Buy with Increased Target to $67 on, Feb 1st, 2013

Martin Auster of UBS, Maintained "BioMarin Pharmaceutical Inc." (BMRN) at Strong Buy with Increased Target from $53 to $67 on, Feb 1st, 2013.

Martin has made no other calls on BMRN in the last 4 months.



There are 2 other peers that have a rating on BMRN. Out of the 2 peers that are also analyzing BMRN, 0 agree with Martin's Rating of Hold.



These are the ratings of the 2 analyists that currently disagree with Martin


  • Gena Wang of "Barclays" Maintained at Buy with Increased Target to $54 on, Tuesday, November 6th, 2012
  • Michelle Gilson of "Canaccord Genuity" Maintained at Strong Buy with Increased Target to $56 on, Monday, November 5th, 2012